Lekooporność nowotworów - problem nie tylko u ludzi

• Autorzy: Szyszko K. , Pawlowski K. M. , Motyl T. , Krol M.

Warianty tytułu

EN

Chemoresistance in cancer: not only a human problem

• Języki publikacji: PL

Abstrakty

EN

Chemoresistance is the main problem in human and veterinary oncology. The most important mechanism of chemoresistance is the expression of efflux pumps from the ABC superfamily, which remove drugs from cancer cells, thus rendering the treatment ineffective. The most important efflux pumps are P-glycoprotein (PGP), multidrug resistance protein 1 (MRP1), multidrug resistance protein 3 (MRP3), and breast cancer resistance protein (BCRP). In humans the expression of efflux pumps, their mechanism of action, and substrates are well described. Little is known, however, about chemoresistance in veterinary medicine. Only a few experiments have been performed, using canine mammary tumors, but the expression of efflux pumps and their substrates are still insufficiently researched. Moreover, preliminary data suggest great differences between various species. This fact underlines the need for a thorough examination of efflux pump substrates in animals because veterinary patients are usually treated according to human chemotherapy protocols.

Słowa kluczowe

PL

nowotwory; komorki nowotworowe; lekoopornosc; bialka ABC; pompy blonowe; glikoproteina P; opornosc wielolekowa; bialko MRP; bialko BCRP

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2011
• Tom: 67
• Numer: 07
• Opis fizyczny: s.453--457,tab.,bibliogr.

Twórcy

autor

Szyszko K.

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego, ul.Nowoursynowska 159, 02-776 Warszawa

autor

Pawlowski K. M.

autor

Motyl T.

autor

Krol M.

Bibliografia

• 1.Bergman P. J., Oglinie G. K., Powers B. E.: Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J. Vet. Intern. Med. 1996, 10, 354-359.
• 2.Borst P., de Wolf C., van de Wetering K.: Multidrug resistance-associated proteins 3,4,5. Eur. J. Physiol. 2007, 453, 661-673.
• 3.Chang G.: Multidrug Resistance ABC transporters. FEBS Letters 2003, 555, 102-105.
• 4.Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G.: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
• 5.Debenham P. G., Kartner N., Siminovitch L., Riordan J. R., Ling V.: DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol. Cell. Biol. 1982, 2, 881-889.
• 6.Deeley R. G., Cole S. P. C.: Substrate recognition and transport by multidrug resistance protein1 (ABCC1). FEBS Lett. 2006, 580, 1103-1111.
• 7.Ejendal K. F. K., Hrycyna C. A.: Multidrug resistance and cancer: The role of The Human Transporter ABCG2. Curr. Protein. Pept. Sci. 2002, 3, 503-511.
• 8.Faneyte I. F., Kristel P. M., Vijver M. J. van de: Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res. 2004, 24, 2931-2939.
• 9.Fromm M. F.: Importance of P-glycoprotein at blood-tissue barrier. Trends Pharmacol. Sci. 2004, 25, 423-429.
• 10.Geyer J., Doring B., Goday J. R., Leidolf R., Moritz A., Petzinger E.: Frequency of the nt230(del4) MDR1 mutation in Collies and related breeds in Germany. Pharmacol. Therap. 2005, 28, 545-551.
• 11.Glavinas H., Krajcsi P., Cserepes J., Sarkadi B.: The role of ABC Transporters in Drug Resistance, Metabolism and Toxicity. Curr. Drug. Deliv. 2004, 1, 27-42.
• 12.Gottesman M., Fojo T., Bates S.: Multidrug Resistance in Cancer: role of ATP-dependent Transporters. Nature Rev. Cancer 2002, 2, 48-58.
• 13.Han K., Kahng J., Kim M.: Expression of functional markers in acute nonlymphoblastic leukemia. Acta Haematol. 2000, 104, 174-180.
• 14.Higgins C. F.: ABC transporters from microorganism to man. Annu. Rev. Cell. Bio. 1992, 8, 67-113.
• 15.Honsha K. U., Schrimer A., Reischauer A., Schoon H. A., Einspanier A., Gabel G.: Expression of ABC-Transport Proteins in Canine Mammary Cancer: Consequences for Chemotherapy. Reprod. Dom. Anim. 2009, 44, 218-223.
• 16.Karayannopoulou M., Kaldrymidou E., Constantinidis T. C.: Adjuvant post-operative chemotherapy in bitches with mammary cancer. J. Vet. Med. A 2001, 48, 85-96.
• 17.Kim M., Tunnquist H., Jackson J., Sgagias S., Yan Y., Gang M., Dean M., Sharp J. G., Cowan K.: The Multidrug Resistance Transporters ABCG2 (Breast Cancer Ressitance Protein1) Effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cell. Clin Cancer. Res 2002, 8, 22-28.
• 18.Konig J., Hartel M., Nies A. T., Martignoni M., Guo J., Buchler M. W., Friess H., Keppler D.: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115, 359-367.
• 19.Król M., Pawłowski K. M., Majchrzak K., Szyszko K., Motyl T.: Why chemotherapy can fail? Pol. J. Vet. Sci. 2010, 13, 399-406.
• 20.Król M., Pawłowski K. M., Skierski J., Turowski P., Majewska A., Polańska J., Ugorski M., Morty R. E., Motyl T.: Transcriptomic "portraits" of canine mammary cancer cell lines with various phenotypes. J. Appl. Genet. 2010, J 51 (2), 169-183.
• 21.Lee J. J., Hughes C. S., Fine R. L., Page R. L.: P-Glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996, 77, 1892-1898.
• 22.Lehne G.: P-glycoprotein as a drug target in the treatment of Multidrug Resistance Cancer. Curr. Drug. Targets 2000, 1, 85-99.
• 23.Lenart K., Szyda A., Kiełbasiński M., Duś D., Podolak-Dawidziak M.: Kliniczne skutki oporności wielolekowej w nowotworach. Onkologia Prakt. Klin. 2005, 1, 18-26.
• 24.Linardi R. L., Natolini C. C.: Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmakokinetic and pharmacodynamic of therapeutic drugs. Cienc. Rural 2006, 36, 336-341.
• 25.Litman T., Druley T., Stein W., Bates S.: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 2001, 58, 931-959.
• 26.Loe D. W., Almqiust K. C., Deeley R. G., Cole S. P.: Multidrug Resistance Protein (MRP) mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. J. Biol. Chem. 1996, 271, 9675-9682.
• 27.Lotsh J., Sharke C., Tegeder I., Geisslinger G.: Drug interactions with patient-controlled analgesia. J. Clin. Pharmacol 2002, 41, 31-57.
• 28.Ma L., Pratt S. E., Cao J., Dantzig A. M., Moore R. E., Slapak C. A.: Identification and characterization of the Canine Multidrug Resistance-associated Protein. Mol. Cancer. Ther. 2002, 1, 1335-1342.
• 29.Mao Q., Unadkat J.: Role of Breat Cancer Resistant Protein (ABCG2) in drug transport. AAPS Journal 2005, 7, E118-E133.
• 30.Mioyshi N., Toyo E., Oishi A., Fujiki M., Misumi K., Sakamoto H., Kameyama K., Shimizu T., Yasuda N.: Immunohistochemical detection of P-glyco-protein (PGP) and multidrug resistance associated protein (MRP) in canine cutaneous mast cell tumors. J. Vet. Med. Sci. 2002, 64, 531-533.
• 31.Nooter K.: The prognostic significance of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 1997, 76, 486-493.
• 32.Nowak M., Madej J. A., Dzięgiel P.: Expression of breast cancer resistance protein (BCRP) in canine mammary adenocarcinomas and adenomas. In Vivo 2009, 23, 705-709.
• 33.Roulet A., Puel O., Gesta S., Lepage J. F., Drag M., Soll M., Alvinerie M., Pineaut T.: MDR1 deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 2003, 460, 85-91.
• 34.Simon D., Knebel J. W., Baumgartner W., Aufderheide M., Meyer-Lindenberg A., Nolte I.: In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. Am. J. Vet. Res. 2001, 62, 1825-1830.
• 35.Simon D., Schoenrock D., Baumgartner W., Nolte I.: Postoperative Adjuvant Treatment of Invasive Malignant Mammary Gland Tumors in Dogs with Doxorubicin and Docetaxel. J. Vet. Intern. Med. 2006, 20, 1184-1190.
• 36.Sobral R. A., Honda S. T., Katayama M. L. H., Brentan H., Brentani M. M., Patrao D. F. C., Folgueira M. A. A. K.: Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer. Acta. Vet. Scand. 2008, 50(1), doi: 10.1186/1751-0147-50-27.
• 37.Stavrovskaya A. A., Stromskaya T. P.: Transport Proteins of the ABC Family and Multidrug Resistance of Tumor Cells. Biochemistry (Moscow) 2008, 73, 735-750.
• 38.Stefkova J., Poledne R., Hubacek A.: ATP Binding Cassette ABC Transporters in Human Metabolizm and Diseases. Physiol. Res. 2004, 53, 235-243.
• 39.Steinbach D., Wittig S., Cario G., Vichmann S., Mueller A., Gruhn B., Haefer R., Zintl F., Sauerbrey A.: The multidrug associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patient and T-cell immunophenotype. Blood 2003, 1202, 4493-4498.
• 40.Sun J., He Z. G., Cheng G., Wang S. J., Hao X. M., Zan M. J.: Multidrug Resistance P-glycoprotein:crucial significance in drug disposition and interaction. Med. Sci. Monit. 2004, 10, RA5-14.
• 41.Takebayashi Y., Nakayama K., Fujioka T., Kanzaki A., Mutho M., Uchida T., Miyazaki K., Ito M., Fukumoto M.: Expression of multidrug resistance associated transporters (MDR1, MRP1, LRP and BCRP) in porcine oocyte. Int. J. Mol. Med. 2001, 7 (4), 397-400.
• 42.Tyden E., Bjornstrom H., Tjalve H., Larsson P.: Expression and localization of BCRP, MRP1 and MRP2 in intestines, liver and kidney in horse. J. Vet. Pharmacol. Ther. 2010, 33 (4), 332-340.
• 43.Versantvoort C. H. M., Broxterman H. J., Lankelma J., Feller N., Pinedo H. M.: Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 1994, 48, 1129-1136.